- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | 253 | EQS Group (EN) | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
20.08.2025 / 16:37 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 04.08. | Pharming Group N.V.: Pharming Group to participate in August investor conference | 383 | GlobeNewswire (Europe) | Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conference... ► Artikel lesen | |
| 31.07. | Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M | 9 | Seeking Alpha | ||
| 31.07. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 31.07. | Pharming reports Q2 results | 2 | Seeking Alpha | ||
| 31.07. | Pharming Group N.V.: Pharming Group reports second quarter and first half 2025 financial results and provides business update | 513 | GlobeNewswire (Europe) | Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased... ► Artikel lesen | |
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 17.07. | Pharming Group N.V.: Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31 | 403 | GlobeNewswire (Europe) | Leiden, the Netherlands, July 17, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second... ► Artikel lesen | |
| 24.06. | Pharming Group N.V. - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 24.06. | Pharming Group N.V.: Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis | 8 | GlobeNewswire (USA) | ||
| 11.06. | Pharming Group N.V. - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 11.06. | Pharming Group N.V.: Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders | 451 | GlobeNewswire (Europe) | Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM)... ► Artikel lesen | |
| 28.05. | Pharming Group N.V.: Pharming Group to participate in June investor conferences | 472 | GlobeNewswire (Europe) | Leiden, the Netherlands, May 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences... ► Artikel lesen | |
| 09.05. | Pharming GAAP EPS of -$0.02 beats by $0.01, revenue of $79.09M beats by $15.15M | 3 | Seeking Alpha | ||
| 08.05. | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 08.05. | Pharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business update | 652 | GlobeNewswire (Europe) | First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting... ► Artikel lesen | |
| 30.04. | Pharming Group N.V.: Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director | 5 | GlobeNewswire (USA) | ||
| 30.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 25.04. | Pharming Group N.V.: Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) | 6 | GlobeNewswire (USA) | ||
| 24.04. | H.C. Wainwright maintains Buy rating on Pharming Group stock | 17 | Investing.com | ||
| 24.04. | NICE issues final guidance endorsing Pharming's APDS therapy | 3 | Pharmaceutical Business Review |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 9,760 | +0,56 % | ARK Invest: Cathie Wood setzt auf Biotech-Wert Intellia und reduziert DraftKings-Position | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,131 | +1,36 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
| CENTOGENE | 0,110 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 3,910 | -0,03 % | Atai Life Sciences stock surges on AbbVie's psychedelic drug acquisition | ||
| BIOMERIEUX | 119,40 | +0,42 % | J.P. Morgan favors bioMérieux over Diasorin in new coverage call | ||
| CYCLACEL | 6,780 | -2,21 % | Cyclacel Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| GENUS | 30,400 | -0,65 % | Genus - Notification of Major Holdings | ||
| ANAPTYSBIO | 17,600 | +1,15 % | AnaptysBio, Inc.: Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update | Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial;... ► Artikel lesen | |
| AKESO | 17,400 | +2,35 % | Akeso, Inc.: Akeso's 2025 Interim Results: Commercial Sales Reach New All-Time Highs | IO 2.0 + ADC 2.0 Strategy Builds a "Next-Generation" Platform with Global Competitive Edge
Key Highlights:
Final analysis of HARMONi-A Study: Ivonescimab met the... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,935 | +4,47 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| ABIONYX PHARMA | 2,910 | +1,04 % | ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 2nd Quarter 2025 | Regulatory News:
ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's... ► Artikel lesen | |
| MEIRAGTX | 6,400 | +2,40 % | MeiraGTx Reports Second Quarter 2025 Financial and Operational Results | - Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX)... ► Artikel lesen | |
| MAAT PHARMA | 4,640 | -7,94 % | MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology | Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg currently under review for potential approval by the EMA and MaaT033... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,062 | -1,11 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2025 | GOTHENBURG, Sweden, August 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2025 is now available, in Swedish, on the... ► Artikel lesen |
PHARMING GROUP NV ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +5,04 % bei einem Aktienkurs von 12,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.